Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.56 |
| ▸ | CALM1 | P0DP23 | 2/20 | 0.53 |
| ▸ | IGF1R | P08069 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.46 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8702849 | 0.90 | IGF1R (0.61) | ABCB1CALM1IGF1RALOX15ESR1 | |
| SCHEMBL8704118 | 0.84 | AKR1B1 (0.60) | ABCB1CALM1CYP19A1RAB9ANPC1 | |
| SCHEMBL254705 | 0.84 | KEAP1 (0.63) | CALM1RAB9ANPC1PKMLTA4H | |
| SCHEMBL8702795 | 0.83 | ABCB1 (0.44) | ABCB1CALM1ALOX15ESR1CYP19A1 | |
| SCHEMBL8702001 | 0.83 | FFAR1 (0.48) | ABCB1RAB9ANPC1KDM4ELTA4H | |
| SCHEMBL227115 | 0.82 | ESR1 (0.73) | ABCB1CALM1IGF1RALOX15ESR1 | |
| SCHEMBL30416326 | 0.81 | ABCB1 (0.62) | ABCB1TAAR1 | |
| SCHEMBL4189173 | 0.81 | ABCB1 (0.62) | ABCB1TAAR1 | |
| SCHEMBL15079871 | 0.81 | MAPT (0.51) | RAB9ANPC1PKMALDH1A1HPGD | |
| Batatasin Iv SCHEMBL30523841 | 0.80 | AKR1B1 (0.70) | ABCB1CALM1RAB9ANPC1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3542780-B1 | SERIES OF SKIN-WHITENING (LIGHTENING) COMPOUNDS | UNIGEN INC (US) | 2022-01-19 | — | — | EP | disclosed |
| EP-3542780-A1 | SERIES OF SKIN-WHITENING (LIGHTENING) COMPOUNDS | Unigen, Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| EP-2323612-B1 | SERIES OF SKIN-WHITENING (LIGHTENING) COMPOUNDS | UNIGEN INC (US) | 2019-07-10 | — | — | EP | disclosed |
| US-20110009447-A1 | Substituted Benzoic Acid Amides and Use thereof for the Inhibition of Angiogenesis | SCHERING AG (DE) | 2011-01-13 | — | — | US | disclosed |
| EP-1280776-B1 | SUBSTITUTED BENZOIC ACID AMIDES AND USE THEREOF FOR THE INHIBITION OF ANGIOGENESIS | BAYER SCHERING PHARMA AG (DE) | 2009-10-21 | — | — | EP | disclosed |
| EP-1280776-A1 | SUBSTITUTED BENZOIC ACID AMIDES AND USE THEREOF FOR THE INHIBITION OF ANGIOGENESIS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001081311-A1 | SUBSTITUTED BENZOIC ACID AMIDES AND USE THEREOF FOR THE INHIBITION OF ANGIOGENESIS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-11-01 | — | — | WO | disclosed |
| EP-0844000-A1 | Use of alpha, omega-diarylalkane derivatives in the treatment and prevention of psychosis | SANKYO COMPANY LIMITED (JP) | 1998-05-27 | — | — | EP | disclosed |
| US-5556864-A | TREATMENT OF CIRCULATORY DISEASES AND PSYCHOSIS | SANKYO COMPANY, LIMITED (JP) | 1996-09-17 | — | — | US | disclosed |
| EP-0600717-A1 | Phenoxyalkylamines, -pyrrolidines and -piperidines for the treatment and prevention of circulatory diseases and psychosis | SANKYO COMPANY LIMITED (JP) | 1994-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009447-A1 | Substituted Benzoic Acid Amides and Use thereof for the Inhibition of Angiogenesis | VEGFA, EGLN2, HIF1AN | ABCB1 984/4885CALM1 1235/4885IGF1R 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.